To confirm and extend these data, other NSCLC patients under PD-1/PD-L1 blockade were analyzed, showing a significant association between a high percentage of circulating PD-L1+CD11b+ cells at baseline and an objective clinical response. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.